Business Description
Silence Therapeutics PLC
ISIN : US82686Q1013
Share Class Description:
SLN: ADRTotal Employee Number:
88Description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 515.28 | |||||
Equity-to-Asset | 0.43 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -5.36 | |||||
Beneish M-Score | 31.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -73.9 | |||||
3-Year EBITDA Growth Rate | -0.2 | |||||
3-Year EPS without NRI Growth Rate | -2.9 | |||||
3-Year FCF Growth Rate | 9.6 | |||||
3-Year Book Growth Rate | 21.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 341.04 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.42 | |||||
9-Day RSI | 83.29 | |||||
14-Day RSI | 76.63 | |||||
3-1 Month Momentum % | 25.05 | |||||
6-1 Month Momentum % | 7.1 | |||||
12-1 Month Momentum % | 19.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.83 | |||||
Quick Ratio | 9.83 | |||||
Cash Ratio | 6.7 | |||||
Days Sales Outstanding | 122.46 | |||||
Days Payable | 27541.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.5 | |||||
Operating Margin % | -9187.25 | |||||
Net Margin % | -8943.86 | |||||
EBITDA Margin % | -9124.91 | |||||
FCF Margin % | -7820.74 | |||||
OCF Margin % | -7814.66 | |||||
ROE % | -224.42 | |||||
ROA % | -50.44 | |||||
ROIC % | -233.67 | |||||
3-Year ROIIC % | -397.36 | |||||
ROC (Joel Greenblatt) % | -4302.84 | |||||
ROCE % | -57.66 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 19.63 | |||||
PS Ratio | 371.81 | |||||
PB Ratio | 6.38 | |||||
Price-to-Tangible-Book | 8.18 | |||||
EV-to-EBIT | -3.19 | |||||
EV-to-EBITDA | -3.22 | |||||
EV-to-Forward-EBITDA | -2.86 | |||||
EV-to-Revenue | 293.41 | |||||
EV-to-Forward-Revenue | 13.35 | |||||
EV-to-FCF | -3.75 | |||||
Price-to-GF-Value | 43.76 | |||||
| Price-to-Net-Current-Asset-Value | 8.53 | |||||
| Price-to-Net-Cash | 71.89 | |||||
Earnings Yield (Greenblatt) % | -31.35 | |||||
FCF Yield % | -20.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Silence Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.839 | ||
| EPS (TTM) ($) | -1.62 | ||
| Beta | 2.6502 | ||
| 3-Year Sharpe Ratio | 0.49 | ||
| 3-Year Sortino Ratio | 0.92 | ||
| Volatility % | 67.52 | ||
| 14-Day RSI | 76.63 | ||
| 14-Day ATR ($) | 0.72505 | ||
| 20-Day SMA ($) | 7.1135 | ||
| 12-1 Month Momentum % | 19.86 | ||
| 52-Week Range ($) | 4.19 - 10.63 | ||
| Shares Outstanding (Mil) | 47.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Silence Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Silence Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 41 days | ||
| General meeting for 2026 | 2026-06-16 08:00 | 7.00 (+3.09%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 16:55 | 6.37 (-0.31%) | ||
| H.C. Wainwright BioConnect Investor Conference | 2026-05-19 14:00 | 6.23 (+1.96%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 7.36 (+3.37%) | ||
| Annual report for 2025 | 2026-03-05 | 5.78 (+4.33%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 5.78 (+4.33%) | ||
| Guidance call for 2025 | 2025-12-10 12:35 | 6.20 (-9.88%) | ||
| Jefferies Global Healthcare Conference | 2025-11-19 08:00 | 6.75 (+0.75%) |
Show
Entries
Silence Therapeutics PLC Frequently Asked Questions
What is Silence Therapeutics PLC(SLN)'s stock price today?
The current price of SLN is $10.07. The 52 week high of SLN is $10.63 and 52 week low is $4.19.
When is next earnings date of Silence Therapeutics PLC(SLN)?
The next earnings date of Silence Therapeutics PLC(SLN) is 2026-08-07 Est..
Does Silence Therapeutics PLC(SLN) pay dividends? If so, how much?
Silence Therapeutics PLC(SLN) does not pay dividend.
Guru Commentaries on NAS:SLN
No articles.
Press Release
Articles on Silence Therapeutics PLC
No articles.
Headlines
See More- 1
Jun 12, 2026
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Benzinga • 9:47am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers